PHARMACEUTICAL COMPOSITION FOR TREATING AGING-ASSOCIATED DISEASES, CONTAINING PROGERIN EXPRESSION INHIBITOR AS ACTIVE INGREDIENT, AND SCREENING METHOD OF SAID PROGERIN EXPRESSION INHIBITOR
Disclosed are a pharmaceutical composition for the treatment of aging-related diseases, comprising a progerin expression inhibitor as an active ingredient, a novel compound inhibitory of binding between progerin and Lamin A, and a pharmaceutical composition for the prophylaxis or therapy of aging-related diseases, comprising the novel compound as an active ingredient. Capable of suppressing the overexpression of progerin and inhibiting binding between progerin and Lamin A, the pharmaceutical composition of the present invention is effective at treating or preventing diseases caused by progerin expression and progerin-Lamin A binding, particularly, renal cancer, leukemia, prostate cancer, and progeria, which are more apt to occur in an aged population. In addition, the screening method of the present invention allows the specific selection of a drug which is simulative of binding between pVHL and progerin, or inhibitory of binding between progerin and Lamin A, thereby developing an effective therapeutic agent for a disease caused in an aged population, such as renal cancer, leukemia, prostate cancer, and progeria.
